DAL vs REGN · P/E 12, rev $61.64B vs P/E 14, rev $14.34B
Delta Air Lines Inc (DAL) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Delta Air Lines Inc (DAL) is a airlines company listed on US. It is led by Ed Bastian.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported DAL revenue for 2024-12-31 was $61.64B. Net income was $3.46B. Revenue was up 6.2% from 2023-12-31 to 2024-12-31. DAL currently screens at market cap $52.18B and trailing P/E 11.6.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
DAL currently screens at market cap $52.18B and trailing P/E 11.6. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the DAL and REGN stock pages for the full models.
Not investment advice.